







an Open Access Journal by MDPI

## State-of-the-Art of Flavivirus Virus Research

Guest Editor:

## Prof. Dr. Tomoyoshi Komiya

Faculty of Health and Medical Sciences, Hokuriku University, Kanazawa 920-1180, Japan

Deadline for manuscript submissions:

31 July 2025

## **Message from the Guest Editor**

Dear Colleagues,

This Special Issue focuses on the ecology, diagnosis, and epidemiology of flaviviruses, focusing with a broad focus on recent advances in infection control and vaccine development. Flaviviruses are insect-borne and include Japanese encephalitis, dengue, and tick-borne viruses. They are, therefore, viruses with regional characteristics. Japanese encephalitis, for example, is widely distributed from the Far East to Southeast and South Asia. Worldwide,

30,000-40,000 cases of Japanese encephalitis are reported annually, but the epidemic has already been largely prevented by routine vaccination, including in Japan and South Korea. This Special Issue aims to cover a wide range of the latest findings on flaviviruses involved in their development and research, with the goal of vaccine prevention and infection control.

Prof. Dr. Tomoyoshi Komiya Guest Editor













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

# **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

### **Contact Us**